Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Hormone Receptor-positive, Heregulin Positive (HRG+), HER2 Negative Metastatic Breast Cancer (Merrimack Pharmaceuticals Inc.)

X
Trial Profile

Randomized Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Hormone Receptor-positive, Heregulin Positive (HRG+), HER2 Negative Metastatic Breast Cancer (Merrimack Pharmaceuticals Inc.)

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 05 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Seribantumab (Primary) ; Fulvestrant
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms SHERBOC
  • Sponsors Elevation Oncology; Merrimack Pharmaceuticals
  • Most Recent Events

    • 07 Nov 2018 Status changed from recruiting to discontinued, as reported in the Merrimack Pharmaceuticals media release.
    • 07 Nov 2018 According to a Merrimack Pharmaceuticals media release, based on the results of the interim analysis of Phase 2 SHERLOC study the company has decided to discontinue development of all ongoing MM-121 programs, including the SHERBOC study.
    • 26 Feb 2018 According to a Merrimack Pharmaceuticals media release, the first patient has been dosed in this study at the UF Health Cancer Center at Orlando Health in the United States.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top